News

blood pressure targets for hypertensive people with chronic kidney disease
Blood pressure targets for hypertension in people with chronic renal disease
Juan Erviti, Luis Carlos Saiz, Leire Leache, José Pijoan, Miguel Menéndez Orenga, Douglas M Salzwedel, Iván Méndez-López
Person taking antihypertensive medication in the morning versus taking in the evening
Evening versus morning dosing regimen drug therapy for hypertension
Chuncheng Wu, Ping Zhao, Ping Xu, Chaomin Wan, Surjit Singh, Shoban Babu Varthya, Shuang-Hong LuoKey messages
pravastatin pills
Pravastatin for lowering lipids
Stephen P Adams, Nima Alaeiilkhchi, Sara Tasnim, James M WrightKey messages
First‐line diuretics versus other classes of antihypertensive drugs for hypertension
Marcia Reinhart, Lorri Puil, Douglas M Salzwedel, James M WrightKey messages
Spring 2023 Cochrane Hypertension newsletter now available!
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.
Winter 2023 Cochrane Hypertension newsletter now available!
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
Luis Carlos Saiz, Javier Gorricho, Javier Garjón, Maria Concepción Salaya, Juan Erviti, Leire LeacheKey messages
Summer 2022 Cochrane Hypertension newsletter now available!
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.
Antiplatelet agents and anticoagulants for hypertension
Eduard Shantsila, Monika Kozieł-Siołkowska, Gregory LipReview questionWe reviewed the evidence that examined whether antiplatelet agents reduced total deaths or major thrombotic events or both in patients with elevated blood pressure (BP) when compared to placebo or other active treatment. We also assessed whether oral anticoagulants reduced total deaths or major thrombotic events or both in these patients when compared to placebo or other active treatment.Background
A new chapter for Cochrane
A new chapter for Cochrane